Literature DB >> 3262520

Interferon-alpha can synergize with interleukin 2 for human in vitro antibody response.

J F Delfraissy1, C Wallon, P Galanaud.   

Abstract

We tested the effect of interferon (IFN)-alpha on the specific anti-2,4,6-trinitrophenyl (TNP) response induced by TNP-conjugated polyacrylamide beads in cultures of purified human B cells. IFN-alpha alone had no effect. Interleukin 2 (IL2) alone had a restorative effect which could be considerably (10X) enhanced by IFN-alpha. This reflected a true synergy most apparent with IL2 concentrations of 10 U/ml and IFN-alpha concentrations of 10(3)-10(5) U/ml. The highest concentrations of IFN-alpha were not inhibitory. In contrast, IFN-alpha did not enhance the effect of an IL2-free T cell-derived supernatant able to support the B cell differentiation. Sequential incubations showed that IFN-alpha acted earlier than IL2 on B cell response. The effect of IFN-alpha was dependent on an efficient interaction between IL2 and its receptor which could be inhibited by a monoclonal antibody toward the CD25 antigen. Thus, IFN-alpha can positively interact with a well defined interleukin, IL2, at a pre or post receptor level to potentiate antibody response.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3262520     DOI: 10.1002/eji.1830180912

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  3 in total

1.  Serum cytokine changes in systemic vasculitis.

Authors:  G E Grau; P Roux-Lombard; C Gysler; C Lambert; P H Lambert; J M Dayer; L Guillevin
Journal:  Immunology       Date:  1989-10       Impact factor: 7.397

Review 2.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

Review 3.  Cytokine-Mediated Regulation of Plasma Cell Generation: IL-21 Takes Center Stage.

Authors:  Leen Moens; Stuart G Tangye
Journal:  Front Immunol       Date:  2014-02-18       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.